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Sclerotic skin manifestations of chronic graft-versus-host disease (ScGVHD) lead to signiﬁcant morbidity,
including functional disability from joint range of motion (ROM) restriction. No superior second-line therapy
has been established for steroid-refractory disease. Imatinib mesylate is a multikinase inhibitor of several
signaling pathways implicated in skin ﬁbrosis with in vitro antiﬁbrotic activity. We performed an open-label
pilot phase II trial of imatinib in children and adults with corticosteroid-refractory ScGVHD. Twenty patients
were enrolled in a 6-month trial. Eight received a standard dose (adult, 400 mg daily; children, 260 mg/m2
daily). Because of poor tolerability, 12 additional patients underwent a dose escalation regimen (adult, 100 mg
daily initial dose up to 200 mg daily maximum; children, initial dose 65 mg/m2 daily up to 130 mg/m2 daily).
Fourteen patients were assessable for primary response, improvement in joint ROM deﬁcit, at 6 months.
Primary outcome criteria for partial response was met in 5 of 14 (36%), stable disease in 7 of 14 (50%), and
progressive disease in 2 of 14 (14%) patients. Eleven patients (79%), including 5 with partial response and 6
with stable disease, demonstrated a positive gain in ROM (range of 3% to 94% improvement in deﬁcit). Of 13
patients with measurable changes at 6 months, the average improvement in ROM deﬁcit was 24.2% (inter-
quartile range, 15.5% to 30.5%; P ¼ .011). This trial is registered at http://clinicaltrials.gov as NCT007020689.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
Sclerotic-type chronic graft-versus-host disease
(ScGVHD) of the skin is characterized by progressive ﬁbrosis
of the dermis and subcutaneous tissues. ScGVHD is generally
a late manifestation of chronic graft-versus-host diseasedgments on page 1089.
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c. on behalf of American Society for Blood and(cGVHD), typically developing >1 year after allogeneic
hematopoietic cell transplantation [1]. It develops in
approximately 15% of patients with cGVHD but poses a
disproportionate challenge to management [1,2]. In a Na-
tional Institutes of Health (NIH) cGVHD natural history study,
patients with ScGVHD had been treated with an average of
4.7 prior therapies, compared with 2.8 therapies for patients
with nonsclerotic cGVHD [3]. ScGVHD may lead to skin pain,
ulceration, restricted chest wall expansion, diminished joint
range of motion (ROM), and contractures, leading toMarrow Transplantation.
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obliterans as a cause of severe cGVHD-related morbidity [4].
Topical treatments, phototherapy, extracorporeal photo-
pheresis, and systemic immunosuppressive agents have
been used for treatment of ScGVHD. Topical therapies are
limited by poor drug penetration to deep ﬁbrotic tissues.
Phototherapy (ultraviolet B and psoralen and ultraviolet A) is
similarly hampered by lack of ultraviolet penetration to deep
dermal tissues. Ultraviolet A-1 phototherapy uses long-
wavelength ultraviolet A light that penetrates into the
dermis and has shown efﬁcacy for ScGVHD in several small
case series; however, it is only available at a limited number
of medical centers in the United States [5-7]. Extracorporeal
photopheresis is also limited by local availability and cost [8].
To date, no single or combination salvage regimen has
demonstrated superior efﬁcacy for ScGVHD.
Imatinib mesylate represents a novel targeted approach
to the management of ScGVHD through inhibition of speciﬁc
signaling pathways implicated in skin ﬁbrosis. Imatinib has
inhibitory activity against platelet-derived growth factor
(PDGF) receptor, among other tyrosine kinases. Elevated
PDGF and its receptor have been found in the skin and
bronchoalveolar lavage ﬂuid in patients with systemic scle-
rosis [9,10]. Stimulatory PDGF receptor antibodies have been
described in patients with systemic sclerosis [11] and
extensive cGVHD [12], suggesting a direct mechanistic link to
skin ﬁbrosis via the PDGF pathway; however, the pathogenic
signiﬁcance of these antibodies remains unclear [13].
Nevertheless, preclinical models of ﬁbrosis in the skin and
lungs suggest a therapeutic beneﬁt of imatinib on tissue
ﬁbrosis [14]. In light of these ﬁndings, we conducted a pilot
phase II study to determine its therapeutic activity using a
multimodality assessment approach including strict
response criteria that correlate with clinically meaningful
functional improvement.
METHODS
Adult and pediatric patients (age  4 years) with a history of ScGVHD,
according to NIH Consensus Group Criteria [15], were enrolled at the NIH
Clinical Center (clinicaltrials.gov identiﬁer: NCT00331968) between
December 2008 and February 2011. The primary objective was clinical
improvement in ScGVHD as measured by change in ROM of 1 or more joints
signiﬁcantly limited by skin ﬁbrosis. Secondary objectives were imatinib
tolerability in patients with ScGVHD, responsiveness and utility of outcome
criteria for ScGVHD evaluation using multimodality assessments (magnetic
resonance imaging [MRI], skin scoring, patient-reported outcomes [PROs]),
functional assessments and biomarker evaluation of disease activity, steady
state level assessment of imatinib, and evaluation of the response of other
cGVHD organ manifestations. The research protocol was approved by the
National Cancer Institute Institutional Review Board, and all participants
provided informed written consent. Imatinib was provided to the National
Cancer Institute under a collaborative agreement between Novartis and the
Division of Cancer Treatment and Diagnosis, National Cancer Institute.
The study design was a single-arm, open-label trial with the primary
endpoint measured at 6 months. Eight patients were initially treated with
400 mg (adults) or 260 mg/m2 (children) imatinib daily in cohort 1. How-
ever, because of poor tolerability and the need for dose reduction to manage
adverse effects in all patients, the protocol was amended. A second cohort of
12 patients were enrolled and treated using intrapatient dose escalation, in
which imatinib was initiated at 100 mg (adults) and 65 mg/m2 (children)
daily and increased to a maximum of 200 mg and 130 mg/m2 daily after 1
month as tolerated (cohort 2). All patients (or parents) were required to
keep a daily medication log and symptom diary.
Inclusion criteria included age  4 years, biopsy-proven ScGVHD
resulting in ROM restriction  25% of normal range at 1 or more joints,
disease refractory to systemic corticosteroids (1 mg/kg/day  14 days) or
patients with stable disease but for whom systemic steroids or calcineurin
inhibitors could not be tapered without disease ﬂare, Karnofsky/Lansky 
60%, absolute neutrophil count  1000/mL, platelet count  50,000/mL, total
bilirubin < 3 times upper limit of normal, transaminase < 5 times upper
limit of normal, normal age-adjusted renal function or creatinine clearance 60/mL/min/1.73 m2, and normal cardiac function. Exclusion criteria were
clinically signiﬁcant systemic illness, including active infection; pregnant or
breast-feeding females or females unwilling to practice birth control during
and for 2 months after treatment; HIV infection; active hepatitis B or C virus
infection; persistent malignancy; ongoing chemotherapy, radiation, or
immunotherapy; prior treatment with imatinib or other tyrosine kinase
inhibitor after transplant; hypersensitivity to imatinib; known brain me-
tastases; and concurrent investigational treatment for cGVHD, including
extracorporeal photopheresis. Eligible patients may not have received
monoclonal antibody therapy within 6 weeks of enrollment. To minimize
drugedrug interactions, patients taking potent inhibitors or inducers of
P450 CYP3-A4 were excluded.
Skin involvement was assessed by comprehensive dermatologic ex-
amination by a dermatologist with expertise in cGVHD (E.W.C.) and
quantiﬁed by separate body surface area (BSA) assessments of epidermal
and ﬁbrotic tissue involvement (ScGVHD). Clinical evidence of ScGVHD was
determined by the presence of skin thickening, rippling or nodularity of
subcutaneous tissues upon deep palpation, and ROM limitation. Histologic
conﬁrmation of ScGVHD was obtained by 6-mm punch skin biopsy. Joint
involvement was determined by a physiatrist with expertise in cGVHD who
performed joint ROM measurements, grip strength, and 2- and 6-minute
walk tests. Joint ROM was compared with percent-predicted ROM for
each joint using values established by the American Academy of Ortho-
pedic Surgeons [16].
NIH cGVHD organ severity (range, 0 to 3) was graded by a transplant
clinician with expertise in cGVHD (K.B.) using the NIH Consensus Criteria
[15]. The average score for each patient was calculated by dividing the total
score by 7 domains in men (skin, eye, oral, joint, gastrointestinal, hepatic,
pulmonary) or 8 domains in women (above 7 domains plus gynecologic)
[17]. The NIH global score was graded “mild,” “moderate,” or “severe” by
consensus at a multidisciplinary meeting [15]. Other subspecialty evalua-
tions included oral medicine (Schubert scale), ophthalmology (Schirmer’s
scoring, eye examination), occupational therapy, and gynecology (female
patients). In addition, the NIH Consensus Response Criteria (Form A/Form B)
were assessed at each time point, and organ responses as per NIH Consensus
Response Criteria were calculated at the 6-month time point [18].
Additional evaluations included pulmonary function testing, MRI at the
site of sclerotic skin involvement, and 10 PROs or performance-based
measures of symptoms, functional status, and quality of life measures:
pincer strength [19], 36-item Manual Ability Measure [20], Jebsen-Taylor
Hand Function Test [21], Disabilities of the Arm, Shoulder and Hand [22],
Grooved Pegboard [23], Assessment of Motor and Process Skills [24], Hu-
man Activity Proﬁle [25,26], Lee Chronic GVHD Symptom Scale [27], Short
Form-36 Health Survey version 2 [28,29], and cGVHD Activity Assessment-
Patient Self Report [18]. Steady state plasma imatinib concentrations were
assessed before the start of treatment and after 1 and 3 months on study in
cohort 2.
The primary endpoint for response to therapy was assessed at 6 months.
Skin scoring and ROM assessment were performed at baseline and every 3
months thereafter. Up to 3 “target” joints with 25% ROM reduction asso-
ciated with skin ﬁbrosis at baseline were included in the primary outcome;
however, if fewer than 3 joints were involved, a single joint or the average
ROM loss from 2 affected joints was used. Joints were prioritized by themost
signiﬁcant functional limitations, excluding joints with confounding reasons
for decreased ROM. Similar ROM assessments have been used to measure
clinical response to treatment of radiation-induced skin ﬁbrosis [30,31]. The
average percentage change in ROM deﬁcit from baseline to 6 months was
obtained based on the number of degrees of ROM change (6 months)/total
ROM deﬁcit (baseline) at each joint, and response was deﬁned as >25% or
greater improvement in the deﬁcit. Progressionwas deﬁned as>25% decline
in ROM deﬁcit (conﬁrmed by a repeat evaluation 2 to 4 weeks later) or >1
steroid pulse during a 3-month period. All others who did not meet the
above criteria for progression or response (ie, between 25% gain and 25%
loss in ROM) were considered stable disease. Maximal response was no
further improvement over 2 sequential 3-month evaluations. Tapering of
immunosuppression was allowed for patients stable or improving after 6
weeks of therapy.
Biomarker Studies
Immunophenotyping
For analysis of T lineage subsets, thawed peripheral blood mononuclear
cells (PBMCs; 107 cells/mL) were stimulated with phorbol myristate acetate
(PMA) (100 ng/mL; Sigma) and ionomycin (1 mg/mL; Sigma) for 6 hours at
37C, adding Golgistop and Golgiplug (BD Biosciences) after 2 hours. After
stimulation, cells were stained with CD3 and CD4; ﬁxed and permeabilized
(eBioscience) for intracellular staining with antibodies against Tbet, IFN-g,
IL-4 (BD Biosciences), FOXP3, IL-17 (eBioscience), IL-13, IL-22 (Biolegend),
and isotope controls; and analyzed on a Gallios ﬂow cytometer (Beckman
Coulter).
Table 1
Patient Demographics (N ¼ 20)
Characteristics Value
Age, median years (range) 51.5 (7-60)
Gender 30% female/70% male
Months from transplant, median (range) 55.4 (12.7-121)
Months from cGVHD diagnosis, median (range) 39.85 (4.8-112)
Myeloablative regimen 55%
Donor match (6/6) 90%
Donor source
Bone marrow 10%
Peripheral blood 90%
Cord 0%
Ethnicity
White 90%
African American 5%
Hispanic 5%
cGVHD category
Overlap 5%
Classic 95%
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The concentration of total transforming growth factor (TGF)-b1 in
plasma was measured using a human TGF-b1 Quantikine ELISA kit (R&D
Systems, Minneapolis, MN) after acid activation of samples according to
the manufacturer’s instructions. The extent of platelet degranulation in
plasma samples was determined using an Imunoclone platelet factor 4
ELISA kit (American Diagnostica, Stamford, CT). Phospho-Smad2 locali-
zation in skin sections was detected by immunohistochemistry as pre-
viously described [32].
B cell activation assays
For analysis of phosphorylation of BLNK and Syk, cryopreserved PBMCs
were thawed and allowed to rest overnight (5  106 cells/mL), as previously
described [33]. One  106 cells were stimulated with 5 mg/mL of the F(ab’)2
fragment of IgM (Jackson Immunoresearch) for 5 minutes at 37C. After
stimulation, cells were immediately ﬁxed (BD cytoﬁx buffer), permeabilized
(BD Perm Buffer III), and stained using antibodies from BD Biosciences:
BLNK (pY84, clone J117-1278) or Syk (pY348, clone 1120-722), PLCg (pY759),
and BTK (pY223). Because only 4 patients had sufﬁcient numbers of viably
frozen PBMCs to evaluate B cell receptor signaling alterations, results for this
assay are reported in supplemental tables and ﬁgures.Late acute 0%
cGVHD presentation
De novo 30%
Quiescent 20%
Progressive 50%
Global NIH cGVHD score
Mild (1) 0%
Moderate (2) 0%
Severe (3) 100%Statistical Analysis
The initial goal of this pilot study was to enroll 10 assessable patients to
assess the change in ROM from baseline to 6 months. With this as the 1
planned primary endpoint, 10 patients would have provided 80% power for a
2-tailed .05 alpha level test to detect 1.0 standard deviation change in ROM
from baseline to 6 months. A paired t-test was to be used to evaluate the
change if the data were normally distributed. If the data were not normally
distributed (P < .05 by a Shapiro-Wilks test), then a Wilcoxon signed rank
test was used instead. To allow for patient dropout due to disease pro-
gression, recurrent malignancy, compliance issues, unacceptable toxicity, or
the need for additional systemic therapy for cGVHD before the 6-month
evaluation, enrollment of up to 13 patients was allowed. Because this was
a small, 1-armed pilot trial, there was no control for natural history or
regression to the mean, but ScGVHD is typically static or progressive and
does not remit or improve spontaneously.
The initial statistical design was revised because none of the initial 8
patients tolerated the 400-mg dose. Efﬁcacy in the 200-mg escalation cohort
was thus evaluated, in accordance with the original power calculations, in a
second cohort of up to 10 assessable patients enrolled. With 8 patients from
the higher dose level and up to 13 total patients from the lower dose level,
the ﬁnal sample size was amended to include up to 21 patients to allow for a
small number of nonassessable patients.
Secondary measures included toxicity, lung manifestations, biomarkers
and PROs, and performance-based endpoints. All secondary endpoints were
considered exploratory, and thus adjustment of P values to control family-
wise error rates was not performed. Differences in secondary outcomes
from baseline to 6 months were determined by a paired t-test after con-
ﬁrming normality of the differences.RESULTS
Demographics and Clinical Characteristics
The general demographics and transplant history of the
study population are shown in Table 1. Most were white (n¼
17) and male (n ¼ 14), the median age was 51.5 years (range,
7 to 60), median time from transplant was 55 months (range,
12.7 to 121), and median time from cGVHD diagnosis was 40
months (range, 4.8 to 112.9). Eight patients were enrolled in
cohort 1 and 12 in cohort 2. cGVHD-speciﬁc characteristics of
the study population are shown in Table 2. Patients were
using a median of 2 immunosuppressive agents (range, 0 to
4), and 13 were on steroids at the time of enrollment.
Almost all patients (n ¼ 18) had 3 affected joints with
>25% ROM deﬁcit for composite ROM analysis. One patient
had 2 affected joints, and 1 had a single joint used for ROM
assessment. Ankle dorsiﬂexion was the most commonly
affected joint (n ¼ 18), followed by shoulder abduction (n ¼
15), shoulder ﬂexion (n ¼ 8), wrist extension (n ¼ 6), wrist
ﬂexion (n ¼ 6), ankle plantar ﬂexion (n ¼ 2), hip internal
rotation (n ¼ 1), and knee ﬂexion (n ¼ 1). The median of the
average NIH cGVHD score was 1.41 (range, .75 to 2.00), with a
median of 5.5 cGVHD-affected organs (range, 2 to 7).Primary Outcome: Change in ROM
Of the 20 participants enrolled, 14 (70%) were assessable
for primary endpoint response at 6 months. Of the 6 patients
who did not make it to the 6-month primary endpoint
analysis, 4 patients voluntarily withdrew before 6 months, 1
was removed for toxicity, and 1 was removed for leukemic
relapse. All patients were included in the toxicity analysis.
Two patients (nos. 3 and 17) experienced progressive dis-
ease, 1 at the 3-month time point (Table 3). Five patients
demonstrated a partial response with >25% improvement in
ROM deﬁcit, and 7 patients had stable disease. Six of the 7
stable patients had a positive gain in ROM deﬁcit (range, 3%
to 22%) but did not meet the 25% threshold for partial
response. Of 13 patients with measurable ROM changes at 6
months, the mean increase in ROMwas 24.2% of the previous
deﬁcit (interquartile range, 15.5% to 30.5%; P ¼ .011 by paired
t-test). Among the 11 patients overall that demonstrated
ROM improvement, the average gain in ROM was 31% of the
previous ROM deﬁcit.Secondary Outcome Measures
Of the 14 subjects included in the primary endpoint
analysis, 13 were assessable for secondary endpoint assess-
ments (1 patient progressed before the 6-month evaluation
and was taken off study). There was no signiﬁcant change in
average NIH cGVHD score (P ¼ .73 by paired t-test), NIH
cGVHD Provider Global Rating Score (P ¼ .47), Lung Function
Score (P ¼ .29), or other cGVHD organ manifestations as per
the NIH cGVHD organ response criteria, including skin score,
at 6 months (Table 4). However, several patients showed a
visible change in skin texture and anecdotally reported skin
softening and improved ﬂexibility despite a lack of signiﬁ-
cant change in ScGVHD BSA (Figure 1). ROM was not signif-
icantly associated with any functional or PROs, including grip
strength, walk times, the Human Activity Proﬁle [25,26], Lee
Chronic GVHD Symptom Scale [27], Short Form-36 Health
Survey [28,29], and cGVHD Activity Assessment-Patient Self
Table 2
Baseline cGVHD Characteristics
Patient
No.
Age Sex Average NIH
cGVHD Score
at Baseline
cGVHD Affected
Organs at
Baseline
Assessable
Joints at
Baseline
Concomitant ISM % BSA Moveable
Sclerosis
(Baseline)
% BSA
Nonmoveable
Sclerosis (Baseline)
Baseline
ROM %
(of Predicted)
1 56 M 1.28 5 3 Pred/tacro 57.15 7.56 37
2 60 M 1.14 4 3 Pred 2.7 56.7 56
3 10 F .75 3 2 MPred/MTX 6.3 36.9 73
4 52 F 1.0 4 3 Pred/siro 0.18 19.98 7
5 30 M 1.48 6 3 Pred/siro/tacro 8.1 77.94 34
6 51 M 1.86 7 3 MPred/tacro/siro/MMF 59.4 0 47
7 55 F 1.90 7 3 Pred/siro/MMF 29.7 32.4 61
8 58 M 1.57 6 3 Tacro 15.3 36.9 35
9 60 M 1.71 7 3 Pred/tacro/siro 3.33 9 42
10 53 M 1.43 5 3 Tacro/MMF 0 8.28 7
11 28 F 1.75 7 3 Pred/siro/MMF 82.08 0 56
12 56 M 1.43 6 3 Tacro/MMF 12.6 8.64 37
13 34 F 1.38 6 3* Pred/tacro 1.8 71.1 27
14 46 M 1.29 5 3 Pred/MMF 5.4 31.5 32
15 55 M 1.43 6 3 Pred/siro 49.77 10.8 22
16 55 M .86 2 1 Siro/MMF 0 9.54 71
17 7 F 1.13 4 3 MPred/tacro/MMF 84.24 0 64
18 21 M 1.57 4 3 Siro 15.84 4.5 54
19 48 M 1.14 4 3 Tacro/MMF 9.45 11.7 33
20 18 M 2.00 7 3 None 0 23.4 5
ISM indicates immunosuppressive medication; Pred, prednisone; tacro, tacrolimus; MPred, methylprednisolone; MTX, methotrexate; siro, sirolimus; MMF,
mycophenolate mofetil.
* Patient 13 started with 3 measureable joints at enrollment on study. She experienced an episode of acute shoulder pain while on study, and evaluation
revealed avascular necrosis of that shoulder. Therefore, only 2 joints were used in the ﬁnal analysis.
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nosuppression within the ﬁrst 6 months, 5 patients with
stable disease had no change in immunosuppression, and 1
patient with progression required an increase in systemic
therapy (Table 4).
Baseline and follow-up MRI studies were obtained for 10
patients (Supplemental Table 1). Most patients exhibited
abnormalities in the skin, subcutis, fascia, or muscle at
baseline. Comparison studies at 6 months demonstrated
persistent/stable MRI ﬁndings in most patients, including 3
of 4 patients who met criteria for partial response.
Adverse Events
All 20 patients enrolled were included in the analysis for
adverse events. Imatinib was generally poorly tolerated at
the 400-mg dose and after dose reduction to 300 mg.Table 3
Primary Endpoint Measures
Patient No. Target Joints Total Baseline
ROM Deﬁcit
(degrees)
Baseline RO
(% Pred)
2 Wrist FL (2), ankle PF 71 56
3 Ankle DF (2) 11 73
7 Wrist EX, wrist FL (2) 80 61
8 Shoulder AB, shoulder FL, ankle DF 169 35
10 Ankle DF (2), Ankle PF 83 7z
12 Shoulder AB, shoulder FL, ankle DF 123 37
13 Hip IR, ankle DF 38 27
14 Shoulder AB, shoulder FL, ankle DF 150 32
15 Shoulder AB (2), ankle DF 191 22
16 Knee FL 39 71
17 Shoulder AB (2), shoulder FL 193 64
18 Wrist EX (2) 60 54
19 Shoulder FL, shoulder AB, ankle DF 128 33
20 Shoulder AB, wrist EX, ankle DF 205 5z
FL indicates ﬂexion; (2), bilateral joints assessed; PF, plantarﬂexion; PR, partial resp
IR, internal rotation; SD, stable disease.
* Based on percent improvement in each joint deﬁcit compared with baseline/n
y Did not reach 25% improvement threshold for PR, but patient experienced RO
z Patients were unable to reach “neutral” position at 1 or more target joints andHypophosphatemiawasmost frequently observed, occurring
in 13 of 20 patients (65%) and requiring oral supplementation
in most individuals (Figure 2). Other adverse reactions
experienced by at least 50% of participants included fatigue
(60%), nausea (60%), and diarrhea (50%). The most clinically
signiﬁcant adverse event was disrupted ﬂuid homeostasis in
60% of patients (12/20). Six patients developed limb edema
(1 grade III), 3 developed facial edema, 1 had trunk edema,
and 2 patients developed pleural effusions, 1 of whom
required hospitalization and supplemental oxygen. Edema
also exacerbated pre-existing pain in sclerotic areas and
appeared to preferentially collect centrally, presumably due
to hidebound skin that restricted peripheral ﬂuid collection.
Notably, several patients complained of worsening muscle
symptoms, particularly pain/cramping (7), myalgias (7), and
creatine phosphokinase elevations (5 grade 1 and 1 grade 2).M Response*
3 month
Response*
6 month
Total 6-Month
ROM Deﬁcit
(degrees)
Response Final Dose
69% 94% 4 PR 300 mg
93% Off-study
progression
Off-study-
progression
PD 300 mg
45% 35% 50 PR 200 mg
13% 16% 150 SDy 200 mg
11% 21% 66 SDy 200 mg
11% 16% 106 SDy 100 mg
65% 61% 17 PR 200 mg
17% 27% 108 PR 200 mg
24% 22% 158 SDy 200 mg
13% 3% 38 SD 200 mg
12% 25% 241 PD 100 mg
6% 2% 59 SD 200 mg
22% 31% 90 PR 200 mg
6% 15% 174 SDy 200 mg
onse; DF, dorsiﬂexion; PD, progressive disease; Ex, extension; AB, abduction;
umber of joints.
M improvement with functional gains.
therefore had negative ROM at baseline.
Table 4
Select cGVHD Response Criteria Measures
Patient
No.
Imatinib ROM
Response
(6 mo)
Total Skin
Score (Baseline)
Total Skin
Score (6 mo)
NIH cGVHD
Provider Global
Rating Score
(Baseline)
NIH cGVHD
Provider Global
Rating Score
(6 mo)
LFS
(Baseline)
LFS
(6 mo)
Change in
Immunosuppression
2 PR 66.6 54 5 4 2 2 Y Pred 20 mg qd to 5 mg qod
3 PD 43.38 n/a 3 n/a 9 n/a Y MPred 16 mg qod to 4 mg qod
7 PR 66.24 55.53 6 8 3 8 YPred: 24 mg qd to 20 mg qd
8 SD* 53.1 55.26 6 7 5 6 No change
10 SD* 10.8 6.12 5 4 3 3 No change
12 SD* 21.24 30.06 6 7 4 5 YTacro 2 mg qam 1.5 mg qpm to
.5 mg bid
13 PR 79.2 62.28 6 4 4 4 PredY 25 mg qd to 15 mg qd;
Tacro Y 2 mg bid to 1 mg bid
14 PR 39.96 40.5 7 6 5 5 PredY 2.5 mg qd to 2.5 mg qod
15 SD* 71.46 61.83 7 6 7 6 YSiro: 2 mg qd to 1 mg qd
16 SD 9.54 8.1 5 4 3 2 No change
17 PD 84.96 85.11 6 8 5 6 Pred wean then [ to 12.5 mg bid;
Tacro[1.0 bid to 1.5 mg bid
18 SD 26.64 24.3 8 8 8 8 No change
19 PR 21.15 37.8 8 5 9 9 MMF Y 1 g/bid to d/c’d
20 SD* 23.4 25.2 8 8 2 2 No change
LFS indicates lung function score; d/c’ed, discontinued.
* Did not reach 25% improvement threshold for PR, but patient experienced ROM improvement with functional gain.
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4), which has been previously reported with imatinib ther-
apy [34].
Of note, adverse events appeared to be dose related, and
patients rechallenged at lower doses generally tolerated
treatment better. All patients who experienced signiﬁcant
grades 2 to 3 edema or ﬂuid disturbance that required
discontinuation of treatment were receiving the 400-mg
daily dose of imatinib. In addition, in the second cohort of
subjects who received 100mg for 1 month, then increased to
200 mg daily, several adverse events increased in either
severity or frequency with the increase in dose. For example,
many patients experienced low-grade hypophosphatemia
during the ﬁrst month, which increased in severity with the
dose increase. Gastrointestinal side effects (nausea, vomiting,
diarrhea), rarely reported at the 100-mg dose level, were
common after the increase to 200 mg. In contrast, adverse
events such as fatigue and muscle cramping frequently
started at the lower dose of 100 mg daily but appeared to
subside over time.Steady State Serum Levels of Imatinib Therapy in ScGVHD
Because of the poor tolerability at the 400-mg daily dose
level, imatinib serum levels were measured in the second
cohort to determine whether higher than anticipated drug
levels were associated with the increased toxicity observedFigure 1. Improvement in skin tightness after imatinib therapy. (A) Baseline. (B) After
in rippled appearance of the skin (dose, 200 mg daily). (C) End of active treatment (9
ROM. (D) One year after ending active treatment, patient continues to have increased s
patient 7).in cohort 1. Serum samples were drawn at 1 month (100 mg)
and 2 months (200 mg) on treatment. Steady state serum
imatinib concentrations from 8 patients at the 200-mg daily
dose ranged from 592 to 2255 ng/mL (mean, 1157 ng/mL),
which is within the inhibitory range of the drug on PDGF
receptor (IC50 range,w.1 to .3 mM).
Interestingly, 6 of 8 samples at the 200-mg dose exceeded
the population reference drug level for the 200-mg dose
(Figure 3). In 3 patients, the observed drug level was >2-fold
higher than expected by the population reference. One of
these patients was a 7-year-old subject receiving 100 mg
(w150 mg/m2). Although she had the highest measured
imatinib serum level (2255 mg/L), she reported only grades 1
to 2 adverse events (mostly gastrointestinal), with the
exception of grade 3 transaminitis possibly related to ima-
tinib. Drugs known to interfere with imatinib metabolism
were not permissible while on study, suggesting that poly-
pharmacy or decreased hepatic drug metabolism may in-
crease the imatinib in the cGVHD setting. One patient (no.18)
suspected of poor drug compliance had nondetectable levels
at both time points.TGF-b Studies
Levels of TGF-b1 in plasma were normalized to platelet
factor 4 levels to account for TGF-b1 derived from platelet
degranulation during sample preparation. The normalized6 months of treatment, there is increased pigmentation but marked reduction
months), there is persistent pigmentation but overall marked improvement in
oftening of skin ﬁbrosis and reduction in hyperpigmentation (partial response,
Figure 2. Adverse events. Waterfall plot reveals adverse reactions to imatinib in patients with ScGVHD (N ¼ 20). Green bars represent grade 1 adverse events, blue
bars represent grade 2 adverse events, and orange bars represent grade 3 adverse events.
Figure 3. Pharmacokinetics of imatinib treatment in patients with ScGVHD.
Data for steady state serum levels in 8 patients receiving imatinib treatment in
cohort 2. Levels are superimposed on 100-mg and 200-mg daily dose popu-
lation controls, shown in black and red, respectively. Patients with ScGVHD
show much higher than expected levels at the 200-mg dosing level. One pa-
tient had no detectable levels at either time point (not shown).
K. Baird et al. / Biol Blood Marrow Transplant 21 (2015) 1083e10901088levels showed no obvious correlation to outcomes, although
levels in most patients were slightly decreased at 3 months
and rose again at 6 months (Supplemental Figure 1).
Immunohistochemistry staining of skin for phospho-Smad2,
a marker for activation of the TGF-b signaling pathway,
showed no appreciable change pre- and post-treatment
(Supplemental Table 2).
Immunophenotyping
Although the number of patient samples was small, no
discernable pattern or change in frequency or absolute
numbers of the regulatory T cells, Th1, Th17, or Th2
lymphocyte populations was noted (Supplemental Figure 2).
DISCUSSION
To our knowledge, this is the ﬁrst prospective clinical trial
of imatinib speciﬁcally for treatment of sclerotic skin cGVHD,
although several studies have evaluated the use of imatinib
in the steroid-refractory cGVHD setting [35-37]. Using ROM
improvement as a surrogate marker of disease response
obviates many of the limitations associated with skin scoring
of cGVHD identiﬁed in previous studies, which rely on
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improvement may not be clinically meaningful. In fact,
several patients in the current study reported subjective
improvement in skin softening but failed to demonstrate a
decrease in overall BSA involvement, consistent with a
qualitative rather than quantitative response that is difﬁcult
to capture using currently recommended skin scoring
systems.
To date, there is conﬂicting evidence regarding the efﬁ-
cacy and tolerability of imatinib for steroid-refractory
ScGVHD. Two early European case series reported response
rates of 50% [38] and 79% [35]; more recently, improved
overall survival was found in patients responding to imatinib
therapy [36]. In contrast, a larger retrospective review of 39
cases of treatment-refractory ScGVHD treated with imatinib
showed limited responses and poor tolerability [39]. The
authors found a 30% overall response rate and only 1 com-
plete response. Additionally, they found high rates of ﬂuid
retention, similar to the present study. Poor tolerability and
limited responses were also reported in a small pilot study
for pulmonary cGVHD [40] and a phase I dose escalation
study for steroid-refractory cGVHD [37]. Responses were
seen in 40% of patients, including 4 of 6 patients with
ScGVHD. As in these prior studies, our study, which required
sclerotic skin involvement, showed imatinib to be poorly
tolerated. Many adverse events encountered manifested as
worsening of pre-existing baseline symptoms such asmuscle
cramping, tinnitus, and edema. Acral edema was particularly
uncomfortable in patients with hidebound skin, and several
patients also experienced central ﬂuid shifts (trunk, pulmo-
nary, pleural).
A major goal of the current trial was to use an outcome
measure that would be sensitive to change and represent
meaningful clinical improvement. For this reason, joint ROM
at a markedly restricted joint, measured by an experienced
physiatrist, was chosen, along with a battery of functional
and quality of life measures designed to fully characterize
disease burden and response. Given that the NIH referral
population is enriched for patients with refractory and long-
standing skin disease, we believe that the ROM improve-
ments shown represent meaningful beneﬁt in a subset of
patients. It is possible that the drug would show greater ef-
ﬁcacy if initiated closer to the time of onset of skin ﬁbrosis
rather than after a prolonged period of joint restriction.
Furthermore, the trajectory of improvement in skin ﬁbrosis is
slow, and therefore subtle improvements in skin softening
may be difﬁcult to accurately quantify. It is unclear why the
various PROs and performance scales did not reﬂect changes
in ROM. It is conceivable that in a resilient population with
long-standing ROM restriction, that even if patients could
perform tasks of daily living more easily after treatment,
these changes may not be adequately captured on the scales
used.
ScGVHD is characterized by variable areas of skin
involvement at different tissue depths, posing a challenge for
accurate assessment in clinical trials based on skin pliability
alone. In addition, edema is a frequent ﬁnding in GVHD,
particularly in patients with active ﬁbrosis, which can be
difﬁcult to differentiate from skin ﬁbrosis and which can be
further complicated by ﬂuid shifts caused by imatinib
treatment. For example, patient 7 had a partial ROM
response but had little change in affected BSA. Nevertheless,
the patient described signiﬁcant improvement, and clinical
photographs showed an appreciable change in the rippled
appearance of her skin over time (Figure 1). MRI has beenproposed as a tool to assess deep-seated sclerotic changes
[41]. Most patients who underwent MRI demonstrated ab-
normalities in the skin, subcutaneous tissue, or fascia.
However, these ﬁndings remained stable at 6 months, even
in patients with signiﬁcant ROM improvement, suggesting
thatMRImay not be sufﬁciently sensitive to change for use as
response tool in the clinical trial setting.
The inclusion of steady state imatinib serum concentra-
tions in this study provides the ﬁrst insight into the poor
tolerability of the drug described in several reports in the
cGVHD setting [37,39]. In some instances, serum levels at the
200-mg dose level were several-fold higher than expected.
Therefore, we conclude that dosing at the 400-mg dose could
lead to toxic levels in these patients. This patient population
is invariably on multiple medications, which cumulatively
may signiﬁcantly inhibit imatinib metabolism.
In our study, evaluation of TGF-b1 plasma levels by ELISA
did not correlatewith outcomes, and immunohistochemistry
staining of skin tissue samples for phospho-Smad2 similarly
showed no appreciable change over time. Consistent with a
role of B lymphocytes in the induction of ﬁbrosis in dermal
ﬁbroblasts in systemic sclerosis [42], our B cell activation
studies showed preliminary evidence that decreased B cell
signaling may correlate with disease response. However,
given the small number of patients, additional testing is
required to conﬁrm these ﬁndings.
Because of the pilot nature of this study, primary re-
sponses were determined at 6 months, and long-term efﬁ-
cacy requires further study. However, all patients were
contacted 1 year after study completion for follow-up. The
outcomes and duration of responses were quite variable.
Several subjects that had improvement in ROM continued to
do well, with no reported loss of ROM after discontinuation.
Two patients that worsened within 2 months after imatinib
discontinuation restarted the drug and again experienced
improvement in skin softness and ROM. Of note, no patients
died while on study, but 2 patients died within 1 year of
coming off treatment (1 subject with progressive disease and
1 with a partial response).
In conclusion, our ﬁndings suggest that treatment with
imatinibmay lead to a functionally meaningful improvement
in joint ROM in a subset of patients with treatment-
refractory disease. Given the lack of a superior salvage ther-
apy for ScGVHD, we believe that low-dose imatinib, given as
part of a multitherapy approach and given earlier in the
course of disease, warrants further exploration in a larger,
randomized study that incorporates the NIH joint/fascia
scale, joint ROM, the photographic ROM [43], and long-term
beneﬁt as assessed by failure-free survival [44].
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